Pope McGlamry – April 29, 2015 - After years of litigation, culminating in a $9 billion jury verdict, Takeda Pharmaceutical has agreed to pay $2.4 billion to settle 9,000 cases involving bladder cancer associated with the use of Actos.
Takeda has not admitted liability, but is willing to resolve these cases to “reduce the uncertainties of complex litigation.”
The settlement of claims will be based on a Master Settlement Agreement that will be binding on Takeda should 95% of eligible plaintiffs participate in the Agreement. The individual settlement amounts will be dependent on Plaintiff’s specific circumstances.
Actos (Pioglitazone) is an oral diabetes medicine designed to control blood sugar levels in patients with Type II diabetes. It is not designed for people with Type I diabetes.
